Q2 details Sales SEK 94.1m (0% vs ABGSC 94.5m), adj.
Högsta orderingången någonsin... Med bred återhämtning i efterfrågan växte orderingången med mer än ...
Ensereptide riktas nu in mot ärrbildning efter kirurgi Promore Pharma antog i mars 2021 en ny strategi för ensereptide (PXL01) och ropocampt...
Q2 details Sales SEK 407m (+13% vs. ABGSCe 361m). Group EBIT SEK 22m (+76% vs.
Redeye reinforces its positive view on Formpipe following a strong Q2 report with record-high ARR gr...
Q-linea's Q2 confirms that the ASTar launch is underway with initial sales and deliveries to the str...
Orexo's DTx segment is still encountering challenges and Zubsolv sales continue to decline.
Redeye maintains its positive view on Orexo after the Q2 report.
Verkkokauppa.com reported Q2 results that were overall somewhat above estimates.
Serneke’s sales, EBIT and net earnings in Q2 2021 were well above our expectations on the group leve...
Redeye thinks Doro's Q2 follows the previous trend.
No big surprises, but Q3 profitability will not much improve Finnair’s Q2 revenue amounted to EUR 11...
The Q2 report showed that Covid-19 is still challenging for Bactiguard, although it showed signs of ...
Projektengagemang reported another robust quarter; although sales continued to decline given lower workforce, sales came roughly in line wit...
Adj. sales up 2% y-o-y but -4% vs. ABGSCe There were two key areas worth emphasising in FormPipe’s Q...
Redeye comments on Safeture's newly announced three-year agreement with SPS.
Hansa’s European Ideflirix launch is well underway in the Nordics, Benelux, U.
Positiv utveckling av uthyrningsgraden Hyresintäkterna för H1 uppgick till EUR 10,5m (EUR 8,5m), dri...
Q2’21 expectations We expect a strong Q2 report with sales of SEK 300m, +26% y-o-y (25% organic, 0% FX, 1% M&A) on normal group comps.
Q2 recurring sales of SEK 325m, +22% y-o-y (9% organic) Vitec reported net sales for Q2’21 of SEK 39...
Lumpy system sales and cloud order intake miss in Q2 Given a challenging market in 2020 due to COVID...
Strong shareholder returns in Q2 NAVPS as of 30 June was SEK 65.
Redeye continues to have a positive outlook on the fundamental prospects of BONESUPPORT following to...
Waystream reported solid numbers in the Q2 report earlier this morning.
Redeye was hoping for slightly stronger earning numbers in the second quarter.
Redeye reinforces its positive view on Hexatronic following the acquisition of REHAU Telecom, adding...
Redeye takes a neutral stance on Proact following a Q2 report with soft System and Cloud growth as c...
